Advanced Solid Tumor — Expanded Access Programs
Overview
Right2Hope maintains a directory of 87 expanded access programs, clinical trials, and compassionate use pathways listed for Advanced Solid Tumor. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with advanced solid tumor programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 21 programs are currently active or recruiting, with the remaining 66 in other lifecycle stages. Sponsors actively running programs in this area include Daiichi Sankyo, Mirati Therapeutics Inc., Anaveon AG, Artios Pharma Ltd, Ascendis Pharma Oncology Division A/S, and others.
By recruiting status
Snapshot of where every Advanced Solid Tumor program currently sits in its lifecycle.
- Active / Recruiting21
- Inactive66
Top sponsors
Organisations running the most Advanced Solid Tumor programs in the directory.
- Daiichi Sankyo4 programs
- Mirati Therapeutics Inc.3 programs
- Anaveon AG2 programs
- Artios Pharma Ltd2 programs
- Ascendis Pharma Oncology Division A/S2 programs
- Avenzo Therapeutics, Inc.2 programs
- BicycleTx Limited2 programs
- Deciphera Pharmaceuticals, LLC2 programs
- DualityBio Inc.2 programs
- GI Innovation, Inc.2 programs
Advanced Solid Tumor programs (87)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on the Safety and Benefits of BNT326 Alone or with Other Treatments for Advanced Cancer — BioNTech SE
- First Human Trial of BLU-924 for Advanced Cancers with KRAS Mutations — Blueprint Medicines Corporation
- Study on OBI-902 for Adults with Advanced Solid Tumors — OBI Pharma, Inc
- Study on IDP-001 for Advanced or Metastatic Solid Tumors — InduPro, Inc.
- Study on Raludotatug Deruxtecan for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study of YL201 for Patients with Advanced Solid Tumors — MediLink Therapeutics (Suzhou) Co., Ltd.
- Study on YL242 for Adults with Advanced Solid Tumors — MediLink Therapeutics (Suzhou) Co., Ltd.
- Study on a New Medicine IPN01195 for Adults with Advanced Solid Tumors — Ipsen
- Study on the Safety and Effectiveness of IPN01203 for Adults with Advanced Solid Tumors Previously Treated with Immune Checkpoint Inhibitors — Ipsen
- Study on ARV-6723 Alone and With Pembrolizumab for Advanced Solid Tumors — Arvinas Inc.
- Study on Lurbinectedin and Berzosertib for Small Cell and High-Grade Neuroendocrine Cancers — National Cancer Institute (NCI)
- Study on Intravenous STX-003 for Advanced Solid Tumors, Alone or with Pembrolizumab — Strand Therapeutics Inc.
- Study on the Safety and Effectiveness of AI-081, a New Antibody Treatment for Advanced Solid Tumors — OncoC4, Inc.
- Study on New Treatment for Patients with Advanced Solid Tumors — Callio Therapeutics
- Study of AU-007, a Monoclonal Antibody for Patients with Advanced or Metastatic Cancer — Aulos Bioscience, Inc.
- Study on AVZO-023 Alone and with Other Treatments for Advanced Solid Tumors — Avenzo Therapeutics, Inc.
- Study of LP-184 for Patients with Advanced Solid Tumors — Lantern Pharma Inc.
- Study of STK-012 Alone and With Other Treatments for Advanced Lung Cancer and Other Cancers — Synthekine
- Study on GTAEXS617 for Adults with Advanced Solid Tumors — Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Study on IMP9064 as a Standalone or Combined Treatment for Advanced Solid Tumors — Impact Therapeutics, Inc.
- Study on XTX301 for Patients with Advanced Solid Tumors — Xilio Development, Inc.
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors — Eikon Therapeutics
- First-in-Human Study of LAT010 for Patients with Advanced Solid Tumors (LIGHTSPEED-1) — Latticon Antibody Therapeutics, Inc
- A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors — Deciphera Pharmaceuticals, LLC
- Study on GEN1286 for Patients with Advanced Solid Tumors — Genmab
- Study on KSQ-001EX, a New Treatment Using Modified Immune Cells for Advanced Solid Tumors — M.D. Anderson Cancer Center
- Study on MRTX0902 for Treating Solid Tumors with KRAS MAPK Pathway Mutations — Mirati Therapeutics Inc.
- Study on OBI-992 for Adults with Advanced Solid Tumors — OBI Pharma, Inc
- Study on SLC-3010 Alone and with Gemcitabine for Advanced Solid Tumors — Selecxine
- Study on IMM-1-104 for Patients with Previously Treated Advanced or Metastatic Solid Tumors with RAS Mutation — Immuneering Corporation
- Study on VLS-1488 for Patients with Advanced Cancer — Volastra Therapeutics, Inc.
- Study on the Safety and Effects of FB849 Alone and with Pembrolizumab in Patients with Advanced Solid Tumors — 1ST Biotherapeutics, Inc.
- A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1) — Anaveon AG
- Study on the Safety and Effectiveness of HB0036 for Advanced Solid Tumors — Shanghai Huaota Biopharmaceutical Co., Ltd.
- Study on BIO-106 Alone and with Pembrolizumab for Advanced Cancers — BiOneCure Therapeutics Inc.
- Study of ANV419 Alone or with Other Approved Treatments for Advanced Skin Melanoma (OMNIA-1) — Anaveon AG
- Study of CPI-0209 for Patients with Advanced Solid Tumors and Lymphomas — Constellation Pharmaceuticals
- Study on DB-1310 for Advanced or Metastatic Solid Tumors — DualityBio Inc.
- A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors — Kahr Medical
- Study on EP0031 for Patients with Advanced RET-altered Cancers — Ellipses Pharma
- Study on Erdafitinib for Patients with Advanced Solid Tumors and FGFR Gene Changes — Janssen Research & Development, LLC
- Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study on LM-24C5 for Advanced Solid Tumors — LaNova Medicines Limited
- Study on OR2805, a Monoclonal Antibody Targeting CD163, Alone and with Other Cancer Treatments — OncoResponse, Inc.
- Study on OR502, a Monoclonal Antibody Targeting LILRB2, Alone and with Other Cancer Treatments — OncoResponse, Inc.
- Study on Oral Alintegimod with Ipilimumab and Nivolumab for Cancer Treatment — 7 Hills Pharma, LLC
- Study on PRT3789 and Pembrolizumab for Advanced or Metastatic Solid Tumors with SMARCA4 Mutation — Prelude Therapeutics
- Study on RNK05047 for Patients with Advanced Solid Tumors or Diffuse Large B-cell Lymphoma (CHAMP-1) — Ranok Therapeutics (Hangzhou) Co., Ltd.
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on TransCon TLR7/8 Agonist With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors — Ascendis Pharma Oncology Division A/S
- Study on DAY101 for Children and Young Adults with Returning or Growing Low-Grade Glioma and Advanced Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on the Safety and Effects of LB101 in Adults with Advanced Solid Tumors — Centessa Pharmaceuticals (UK) Limited
- Study on the Safety and Effectiveness of GI-102 for Patients with Advanced Solid Tumors — GI Innovation, Inc.
- Study on the Safety and Tolerability of TransCon IL-2 β/γ Alone or with Pembrolizumab and/or Chemotherapy in Adults with Advanced Solid Tumors — Ascendis Pharma Oncology Division A/S
- Study on CFI-402257, a New Drug for Solid Tumors and Breast Cancer with Fulvestrant — Treadwell Therapeutics, Inc
- Study on Combining SON-1010 and Atezolizumab for Patients with Platinum-Resistant Ovarian Cancer — Sonnet BioTherapeutics
- Study on EIS-12656 Alone and in Combination for Patients with Certain Advanced Solid Tumors — Eisbach Bio GmbH
- Study on the Safety and Effects of HH2853 — Haihe Biopharma Co., Ltd.
- First-in-Human Study of DB-1305/BNT325 for Advanced or Metastatic Solid Tumors — DualityBio Inc.
- First-in-Human Study of DS-3939a for Patients with Advanced Solid Tumors — Daiichi Sankyo
- Study on GI-101 Alone or with Pembrolizumab, Lenvatinib, or Local Radiotherapy for Advanced Solid Tumors — GI Innovation, Inc.
- Study on JAB-21822 for Adults with Advanced Solid Tumors with KRAS G12C Mutation — Jacobio Pharmaceuticals Co., Ltd.
- Study on Mirdametinib and BGB-3245 for Advanced Solid Tumors — SpringWorks Therapeutics, Inc.
- Study on NUV-868 Alone and with Olaparib or Enzalutamide for Adults with Advanced Solid Tumors — Nuvation Bio Inc.
- Study of IT STX-001 for Patients with Advanced Solid Tumors, Alone or with Pembrolizumab — Strand Therapeutics Inc.
- Phase 1/2 Study of MRTX1719 for Solid Tumors with MTAP Gene Deletion — Mirati Therapeutics Inc.
- Study on TU2218 Alone and with Checkpoint Inhibitors for Advanced Solid Tumors — TiumBio Co., Ltd.
- Study on the Safety and Effectiveness of NUV-1511 for Adults with Advanced Solid Tumors — Nuvation Bio Inc.
- Study on the Safety and Early Effects of TYRA-300 in Advanced Bladder Cancer and Other Tumors with FGFR3 Gene Changes — Tyra Biosciences, Inc
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study on the Safety and Effectiveness of CJRB-101 with Pembrolizumab for Advanced or Metastatic Cancer — CJ Bioscience, Inc.
- Study on BT7480 for Patients with Advanced Cancers Linked to Nectin-4 — BicycleTx Limited
- Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies — BicycleTx Limited
- Study of ART0380 for Patients with Specific Solid Tumors — Artios Pharma Ltd
- Study of ART6043 for Patients with Advanced or Metastatic Solid Tumors — Artios Pharma Ltd
- Study on ATRN-119 for Patients with Advanced Solid Tumors — Aprea Therapeutics
- Study of AVZO-021 for Patients with Advanced Solid Tumors — Avenzo Therapeutics, Inc.
- Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway — Deciphera Pharmaceuticals, LLC
- Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors — Daiichi Sankyo
- Study on MRTX1133 for Patients with Advanced Solid Tumors with a KRAS G12D Mutation — Mirati Therapeutics Inc.
- Study on RP-3500 (Camonsertib) for Advanced Solid Tumors — Repare Therapeutics
- Study of SGN1 in Patients with Advanced Solid Tumors — Guangzhou Sinogen Pharmaceutical Co., Ltd
- Study of TTX-MC138 in Subjects With Advanced Solid Tumors — TransCode Therapeutics
- Study on AFM24 and Atezolizumab for Advanced or Metastatic EGFR-Expressing Cancers — Affimed GmbH
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Study on Vilastobart (XTX101) Alone and with Atezolizumab for Advanced Solid Tumors — Xilio Development, Inc.
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Advanced Solid Tumor to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.